Edition:
United States

Acasti Pharma Inc (ACST.OQ)

ACST.OQ on NASDAQ Stock Exchange Capital Market

1.86USD
26 Sep 2016
Change (% chg)

$-0.03 (-1.59%)
Prev Close
$1.89
Open
$1.93
Day's High
$1.93
Day's Low
$1.86
Volume
8,387
Avg. Vol
15,820
52-wk High
$3.50
52-wk Low
$1.20

Summary

Name Age Since Current Position

Roderick Carter

2016 Executive Chairman of the Board

Jan D'Alvise

2016 President, Chief Executive Officer

Mario Paradis

2015 Chief Financial Officer

Pierre Lemieux

2010 Chief Operating Officer

Laurent Harvey

Vice President- Clinical and Non-Clinical Affairs

Jean-Daniel Belanger

Secretary, Director- Corporate Affairs

Valier Boivin

2013 Independent Director

Jean-Claude Debard

2013 Independent Director

Ronald Denis

2014 Independent Director

Pierre Fitzgibbon

61 2014 Independent Director

Biographies

Name Description

Roderick Carter

Dr. Roderick Carter is Executive Chairman of the Board of the company. Carter held various commercial and research leadership roles including Merck and Pfizer. He was vice-president of clinical development at Reliant Pharmaceuticals, which developed the omega-3 cardiovascular drug Lovaza and today is a wholly owned subsidiary of GlaxoSmithKline.

Jan D'Alvise

Ms. Jan D'Alvise is appointed as President, Chief Executive Officer of the Company. effective June 1, 2016. She has extensive experience in diagnostics, medical devices, pharmaceuticals and drug discovery research tools. Until recently, Ms. D'Alvise was the President and Chairman of Pediatric Bioscience. Before that, she was the CEO of Gish Biomedical, a cardiopulmonary medical device company. Prior to Gish, Ms. D'Alvise was the CEO of the Sidney Kimmel Cancer Center (SKCC), a drug discovery research institute. From 1995, she was also the Co-Founder and Executive VP/COO of Metrika Inc., and in 1999 was the Co-Founder/President/CEO/ Chairman of NuGEN, Inc. Ms. D'Alvise built both companies from technology concept through to successful regulatory approvals, product introduction and sustainable revenue growth. Prior to 1995, Ms. D'Alvise was a VP of Drug Development at Syntex/Roche and Business Unit Director of their Pain and Inflammation business, and also VP of Commercial Operations at SYVA, (Syntex's clinical diagnostics division), and began her career with Diagnostic Products Corporation (DPC). Ms. D'Alvise has a B.S. in Biochemistry from Michigan Technological University. She has completed post-graduate work at the University of Michigan, Stanford University, and the Wharton Business Schools. Jan has served on the board of numerous private companies and non-profits, and is an Entrepreneur-in-Residence for the von Liebig Institute for Entrepreneurship at the University of California, San Diego.

Mario Paradis

Mr. Mario Paradis has been appointed as Chief Financial Officer of the Company., effective August 24, 2015. Mr. Paradis was formerly vice president and CFO at Atrium, which was acquired in 2014 by corporations backed by Permira funds in a transaction valued at over $1.1 billion. Prior to this, he held roles of increasingly authority at Aeterna Zentaris, most notably as vice president finance and administration & corporate secretary. Mr. Paradis began his career at PricewaterhouseCoopers, where he successfully held senior positions primarily in audit and tax. Mr. Paradis is a member of the Canadian Chartered Professional Accountants. He holds a bachelor's degree in business, with a specialty in accounting, from Universite du Quebec a Trois-Rivieres.

Pierre Lemieux

Dr. Pierre Lemieux Ph.D. serves as the Chief Operating Officer of Acasti Pharma Inc., Dr. Pierre Lemieux has been the Chief Operating Officer of the Corporation since April 12, 2010. He holds a post-doctoral degree in Oncology from the Health Science Center, University of Texas (San Antonio), United States, and a PhD in biochemistry from Laval University, Canada, jointly with University of Nottingham, England. Prior to joining the Corporation, Dr. Lemieux was the President, Chief Executive Officer and the chairman of the board as well as being the founder of Technologie Biolactis Inc., a late-stage biotechnology company specialized in the valorization of proteins to better serve the nutraceutical, cosmetic and pharmaceutical industries.

Laurent Harvey

Mr. Laurent Harvey serves as the Vice President, Clinical and Non-Clinical Affairs of the company. Laurent has more than 25 years’ experience in the biopharmaceutical industry, primarily in drug development and clinical research. Before joining Acasti Pharma, he occupied different management positions at Bristol-Myers Squibb, Æterna-Zentaris, Innodia, Bellus Health and KLOX Technologies. During his career, he participated in many national and international clinical programs in various therapeutic fields such as cardiovascular, endocrinology, oncology and neurology. Laurent holds a Bachelor’s degree in pharmacy and M.Sc in hospital pharmacy, both from Université de Montréal.

Jean-Daniel Belanger

Mr. Jean-Daniel Belanger serves as the Corporate Secretary and Director, Corporate Affairs of the company. Mr. Bélanger is Director Corporate Affairs of the Corporation since November 2012 and Corporate Secretary since June 2014. He is in charge of all corporate, governance and securities law matters of the Corporation. He oversees and leads negotiations on corporate and financing matters and is an integral member of the management team, reporting directly to the President and Chief Executive Officer. He holds a law degree from the Université de Montréal (2005) and is a member of the Quebec Bar since 2006. Prior to joining the Corporation, Jean-Daniel was a partner in a Montreal securities boutique-firm, where he practiced in the areas of mergers and acquisitions, corporate finance and securities, and general corporate and commercial law.

Valier Boivin

Mr. Valier Boivin serves as an Independent Director of Acasti Pharma Inc., Mr. Valier Boivin holds a bachelor’s degree in Economic and Administrative Sciences (UQAC-1973), a master’s degree in Taxation (Université de Sherbrooke, 1978) and a law degree (Université de Montréal, 1985). He has also been a member of the “Barreau du Québec” since 1986 and the “Ordre des comptables agréés du Québec” since 1974. He held the position of Professor at the Université du Québec à Chicoutimi until 1978 and then joined the master’s degree in taxation program as Professor at the Université de Sherbrooke until 1987. Founder (in 1987) of Boivin O’Neil, s.e.n.c., he also practices business law. Specialized in mergers & acquisitions and corporate financing, he acts as legal and strategic counsel to many private and public companies. Since January 2009, he has occupied the position of President of the regional economic intervention fund, FIER Ville-Marie, L.P. Mr. Boivin is also socially involved with various professional associations, non-profit organizations and charitable foundations.

Jean-Claude Debard

Mr. Jean-Claude Debard serves as an Independent Director of Acasti Pharma Inc., Mr. Jean-Claude Debard has been President of M Motors Automobiles France, Subaru France, Daihatsu France, SsangYong France since 2012 and FEA Services as well as an officer of Frey Accessories and Parts since 1999 and most recently Executive President of Group Emil Frey France since 2008. Since 1999, Mr. Debard has served on the Oversight Committee of Holding (SERGESA), SsangYong France and Hyundai Finances. Mr. Debard also has a graduate degree in Management and Strategic Management.

Ronald Denis

Dr. Ronald Denis serves as an Independent Director of Acasti Pharma Inc. Dr. Ronald Denis has been Chief of Surgery and director of the Trauma Program at Hôpital du Sacré-Coeur in Montréal since 1997. Since 1987, Dr. Denis has also been medical co-director of the Canadian Formula 1 Grand Prix. Dr. Denis sits on several scientific boards and management committees.

Pierre Fitzgibbon

Mr. Pierre Fitzgibbon serves as the Independent Director of the comapny. Mr. Fitzgibbon was the President and Chief Executive Officer of Atrium Innovations Inc., a leader in the development, manufacturing and marketing of added value products for the health and nutrition industry, which was recently sold to corporations backed by the Permira funds in a transaction valued at over $1.1 billion. Prior to joining Atrium Innovations, Mr. Fitzgibbon was Vice-Chairman of National Bank Financial and Senior Vice-President, Finance, Technology and Corporate Affairs at National Bank of Canada. He holds a bachelor’s degree in business administration from the École des hautes études commerciales of Montreal and a certificate in general management from Harvard Business School. Mr. Fitzgibbon currently serves on the board of directors of other corporations.